A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)
The goal of this clinical research study is to learn if adding ABT-414 to radiation therapy and temozolomide can help to control glioblastoma better than treatment with radiation therapy and temozolomide alone. The safety of the combinations will also be studied.
Disease Group: Malignant neoplasms of eye brain and other parts of central nervous system
Treatment Agent: ABT-414,Temozolomide
Treatment Location: Both at MDACC & and Other Sites
Sponsor: AbbVie Inc.
IRB Review and Approval Date: 06/07/2016
Recruitment Status: Open
Projected Accrual: 640
Information and next steps
Malignant neoplasms of eye brain and other parts of central nervous system
Phase II/Phase III
For general questions about clinical trials: